Cetera Investment Advisers Acquires 1,466 Shares of Zoetis Inc. $ZTS

Cetera Investment Advisers increased its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 1.3% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 116,714 shares of the company’s stock after acquiring an additional 1,466 shares during the period. Cetera Investment Advisers’ holdings in Zoetis were worth $18,201,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. Vanguard Group Inc. grew its stake in shares of Zoetis by 0.5% in the 1st quarter. Vanguard Group Inc. now owns 41,556,164 shares of the company’s stock worth $6,842,222,000 after buying an additional 189,287 shares during the last quarter. Geode Capital Management LLC boosted its holdings in Zoetis by 0.9% in the second quarter. Geode Capital Management LLC now owns 11,081,301 shares of the company’s stock worth $1,721,356,000 after acquiring an additional 95,294 shares in the last quarter. Polen Capital Management LLC grew its stake in shares of Zoetis by 17.6% in the first quarter. Polen Capital Management LLC now owns 8,796,847 shares of the company’s stock worth $1,448,401,000 after acquiring an additional 1,313,653 shares during the last quarter. Northern Trust Corp grew its stake in shares of Zoetis by 1.2% in the first quarter. Northern Trust Corp now owns 6,504,902 shares of the company’s stock worth $1,071,032,000 after acquiring an additional 78,508 shares during the last quarter. Finally, Goldman Sachs Group Inc. increased its holdings in shares of Zoetis by 2.2% during the first quarter. Goldman Sachs Group Inc. now owns 5,146,024 shares of the company’s stock valued at $847,293,000 after acquiring an additional 109,791 shares in the last quarter. Institutional investors own 92.80% of the company’s stock.

Analyst Ratings Changes

Several analysts recently commented on ZTS shares. Stifel Nicolaus cut their price objective on shares of Zoetis from $140.00 to $130.00 and set a “hold” rating on the stock in a research report on Tuesday. Argus reiterated a “buy” rating and issued a $190.00 target price on shares of Zoetis in a research note on Tuesday, September 9th. Piper Sandler raised their price target on shares of Zoetis from $210.00 to $215.00 and gave the company an “overweight” rating in a research report on Monday, August 11th. Weiss Ratings restated a “hold (c-)” rating on shares of Zoetis in a report on Wednesday, October 8th. Finally, Morgan Stanley lowered their price objective on Zoetis from $211.00 to $175.00 and set an “overweight” rating on the stock in a research report on Monday, November 10th. Six investment analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. According to MarketBeat, Zoetis currently has a consensus rating of “Moderate Buy” and an average target price of $178.89.

Zoetis Price Performance

NYSE ZTS opened at $118.30 on Wednesday. Zoetis Inc. has a one year low of $117.09 and a one year high of $181.85. The stock has a 50-day moving average of $139.63 and a 200 day moving average of $150.90. The company has a debt-to-equity ratio of 1.05, a quick ratio of 1.04 and a current ratio of 1.76. The company has a market capitalization of $52.13 billion, a price-to-earnings ratio of 20.36, a PEG ratio of 2.31 and a beta of 0.90.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Tuesday, November 4th. The company reported $1.70 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.62 by $0.08. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The firm had revenue of $2.40 billion for the quarter, compared to the consensus estimate of $2.42 billion. During the same quarter last year, the firm posted $1.58 EPS. The business’s quarterly revenue was up .5% compared to the same quarter last year. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. On average, sell-side analysts forecast that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 2nd. Shareholders of record on Friday, October 31st will be given a $0.50 dividend. This represents a $2.00 dividend on an annualized basis and a yield of 1.7%. The ex-dividend date of this dividend is Friday, October 31st. Zoetis’s payout ratio is 33.67%.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.